| Clinical data | |
|---|---|
| Pronunciation | /ˌhɛksoʊˈprɛnəliːn/ HEKS-oh-PREN-ə-leen |
| Other names | 4-[2-[6-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets), IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 5–11% (Tmax = 2 hours) |
| Metabolism | COMT (slow O-methylation) |
| Elimination half-life | ~50 minutes (if taken orally) |
| Excretion | Feces (~90%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H32N2O6 |
| Molar mass | 420.506 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| | |
Hexoprenaline is a selective β2 adrenergic receptor agonist used in the treatment of asthma. Hexoprenaline is also used in some countries (such as Russia and Switzerland) as a tocolytic agent (i.e., labor suppressant), with the most common trade name being Gynipral. It is not approved by the United States Food and Drug Administration.
When used as a tocolytic, hexoprenaline is contraindicated in:
It should be used with caution in people with gestational diabetes.
When concomitantly administered:
Hexoprenaline is contraindicated for use with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressant (TCAs), ergot alkaloids, and dihydrotachysterol.